Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Current Leases (2019 - 2025)

Arcadia Biosciences filings provide 7 years of Current Leases readings, the most recent being $11000.0 for Q2 2025.

  • On a quarterly basis, Current Leases fell 98.05% to $11000.0 in Q2 2025 year-over-year; TTM through Jun 2025 was $11000.0, a 98.05% decrease, with the full-year FY2024 number at $155000.0, down 81.81% from a year prior.
  • Current Leases hit $11000.0 in Q2 2025 for Arcadia Biosciences, down from $21000.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $1.1 million in Q3 2021 to a low of $11000.0 in Q2 2025.
  • Median Current Leases over the past 5 years was $943000.0 (2021), compared with a mean of $754500.0.
  • Biggest five-year swings in Current Leases: skyrocketed 62.0% in 2021 and later crashed 98.05% in 2025.
  • Arcadia Biosciences' Current Leases stood at $1.1 million in 2021, then decreased by 5.96% to $1.0 million in 2022, then fell by 15.64% to $852000.0 in 2023, then tumbled by 81.81% to $155000.0 in 2024, then plummeted by 92.9% to $11000.0 in 2025.
  • The last three reported values for Current Leases were $11000.0 (Q2 2025), $21000.0 (Q1 2025), and $155000.0 (Q4 2024) per Business Quant data.